Xeljanz lawsuit attorneys Xeljanz law firm nj nj pa pennsylvaniaXeljanz is Pfizer's brand name for a drug known as tofacitinib citrate. Xeljanz was approved to treat rheumatoid arthritis (“RA”) in 2012, psoriatric arthritis in 2017, and ulcerative colitis in 2018. Xeljanz is a janus kinase 1 and 3 (“JAK”) inhibitor, which blocks enzymes that may cause inflammatory reactions. Because Xeljanz inhibits the immunity system in order to treat patients, it carries a disclosed danger of serious conditions due to infections or related cancers. In relation to safety concerns, Xeljanz has not been approved on the market in the European Union.
Unfortunately, the United States Federal Drug Administration (“FDA”) has unearthed that: “[A]n increased risk of blood clots in the lungs and death when a 10 mg twice daily dose of tofacitinib (Xeljanz, Xeljanz XR) was used in patients with rheumatoid arthritis (RA). FDA has not approved this 10 mg twice daily dose for RA; this dose is just approved in the dosing regimen for patients with ulcerative colitis.”
Do I Have a Claim? What are Xeljanz Side-Effects?
Xeljanz lawsuit law firms pic 3 nj nj pa pennsylvaniaIf you or perhaps a cherished one took 10 mg of Xeljanz twice a day to treat rheumatoid arthritis (“RA”) and suffered some of the following serious injuries or side-effects:
Pulmonary embolism (“PE”) Pulmonary thrombosis (“PT”) Deep vein thrombosis (“DVT”)
You could have a potential claim for compensation against the makers of Xeljanz.
Our Xeljanz lawyers are experienced in MDL litigation cases and in negotiating with pharmaceutical settlement representatives. Contact us, totally free, when you have any questions.
Are You Impacted by the Potential Xeljanz Lawsuits ? You May Be Eligible to Compensation.
Whilst it is still very early and an important amount of Xeljanz lawsuits have not yet been filed, in the event that you or perhaps a loved one have got Xeljanz and suffered an accident, it's strongly recommended that you seek counsel with our Xeljanz attorneys, who're experienced in Xeljanz claims and injuries.
Earlier in 2010 the FDA warned: “Patients shouldn't stop or change your dose of tofacitinib without first talking to your health care professional, as this may worsen your condition. Patients taking tofacitinib should seek medical attention immediately if you experience outward indications of a blood clot in your lungs or other unusual symptoms such as for instance:
Sudden shortness of breath or difficulty breathing Chest pain or pain in your back Paying up blood Excessive sweating Clammy or bluish colored skin”
Stark & Stark Xeljanz attorneys are actively seeking Xeljanz settlements and filing Xeljanz lawsuits against drug makers for patients injured by these potentially defective drugs. If you imagine you have taken Xeljanz and suffered a blood clot injury, the Xeljanz attorneys at Stark & Stark can allow you to assess your potential claims.